Paul Tudor Jones’s Inhibrx INBX Stock Holding History

Paul Tudor Jones’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,373	Closed	-$496K	–	3905
2026 Q1	$496K	Buy	7,373 +2,731	+59%	+$203K	﹤0.01%	2822
2025 Q4	$367K	Buy	+4,642	New	+$316K	﹤0.01%	2919

Other funds holding INBX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Paul Tudor Jones's INBX Position: Q2 2026 in Review

Paul Tudor Jones sold out of Inhibrx (INBX) in Q2 2026, closing a stake of 7,373 shares — an estimated $496K sold.

Paul Tudor Jones first reported a position in INBX in Q4 2025 and held it in 2 quarters. The position peaked at $496K in Q1 2026. 162 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

Paul Tudor Jones reported no remaining Inhibrx position as of Q2 2026 after selling out during the quarter.
Paul Tudor Jones sold 7,373 Inhibrx shares in Q2 2026, an estimated $496K.
Paul Tudor Jones first reported a position in Inhibrx in Q4 2025 and held it in 2 quarters.
Paul Tudor Jones's Inhibrx position peaked at $496K in Q1 2026.
162 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.